DEA Issues Long Awaited Final Order Rescheduling Certain Marijuana Products to Schedule III: What It Means, What It Doesn’t, and What Comes Next - JD Supra
DEA Issues Long Awaited Final Order Rescheduling Certain Marijuana Products to Schedule III: What It Means, What It Doesn’t, and What Comes Next - JD Supra — rescheduling update affecting Pharmaceutical Manufacturing (FDA/DEA).
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on September 3, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Low urgency. Pharmaceutical Manufacturing (FDA/DEA) (branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, compounding outsourcing (503B)) should confirm how it applies to their specific situation before acting. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
DEA Issues Long Awaited Final Order Rescheduling Certain Marijuana Products to Schedule III: What It Means, What It Doesn’t, and What Comes Next - JD Supra
Who it affects
Pharmaceutical Manufacturing (FDA/DEA) (branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, compounding outsourcing (503B))
What you must do
Read the update and assess whether your current setup needs to change.
Deadline
No fixed deadline was published, but changes like this are often enforced quickly — act promptly.
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- CEO Spotlight: Larry Lee - contractpharma.com
- Amgen invests $1bn into new US drug manufacturing facility - Manufacturing Chemist
- Fujifilm Holly Springs Selected for FDA PreCheck Pilot - contractpharma.com
- Catalent Announces $12 Million Expansion Program at Kansas City Facility - contractpharma.com
- Fight over GLP-1 compounding plays out in statehouses, courthouses - The Indiana Lawyer